Stock JAGX JAGUAR HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
0.1569 USD -11.41% Intraday chart for Jaguar Health, Inc. +73.75% +3.63%
Apr. 19 Venture Life renews revolving credit facility with Santander and HSBC AN
Apr. 10 Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Venture Life renews revolving credit facility with Santander and HSBC
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes
Top Premarket Gainers
Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Top Premarket Gainers
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon
Sector Update: Health Care Stocks Rise Tuesday Afternoon
Jaguar Health's Napo Pharmaceuticals Awaits Data on Phase 3 Trial of Crofelemer; Shares Fall
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Jaguar Health Gets Additional 180-Day Grace Period to Regain Nasdaq Compliance
Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome
Jaguar Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Napo Pharmaceuticals Submits Funding Application to BARDA for NP-300 Development
Jaguar Health, Inc. Announces the Results of an Independent Pilot Phase 2 Study of Crofelemer for the Management ofneratinib-Associated Diarrhea
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JAGX Stock
  4. News Jaguar Health, Inc.
  5. Other languages